Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment
Sponsor: Université Catholique de Louvain
Summary
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting MS and is independently associated with an increased risk of developing new MRI lesions within two years of diagnosis (ref. Deltombe et al., PMID: 41004694). This project aims to further explore FCRL5 as a prognostic biomarker, study the role of FCRL5-expressing B cells in MS pathogenesis and the effects of disease-modifying therapies on these subsets.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
90
Start Date
2026-08
Completion Date
2029-12-31
Last Updated
2026-08-26
Healthy Volunteers
Yes
Conditions
Interventions
A blood test every 6 months for MS patients.
A blood test every 6 months for MS patients : Day1, Month 6, Month 12 and Month 24
A single blood draw for the healthy volunteer
A single blood draw for the healthy volunteer
A single blood draw for the group of volunteers with Sjögren's syndrome
A single blood draw for the group of volunteers with Sjögren's syndrome
Locations (1)
Université Catholique de Louvain
Brussels, Belgium